Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. on February 25, 2026. The filing discloses the company's intent to conduct meetings with third parties to present its corporate slide deck. The presentation materials are attached as Exhibit 99.1 and are incorporated by reference.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of upcoming investor communications rather than a financial results announcement.
Material Changes
No material changes to financial performance or operations are reported in this document. The primary event is the scheduled dissemination of corporate presentation materials to third parties.
Guidance, Outlook, and Risks
The attached Exhibit 99.1 contains forward-looking statements subject to cautionary statements within that exhibit. The filing explicitly states that the information, including the presentation, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. Investors should review the specific risks and contingencies detailed in the attached corporate presentation.
Key Facts for Investor Verification
- Verify the content of the corporate presentation attached as Exhibit 99.1 for specific business updates.
- Confirm that the forward-looking statements in the presentation are reviewed alongside their associated risk factors.
- Note that this 8-K does not contain audited or unaudited financial statements for the period.
- Identify Mani Mohindru as the Interim Chief Executive Officer who authorized the filing.